Avery Therapeutics

Jordan Lancaster, Ph.D., CEO

Oct. 8 | 1:30pm | FLW Ballroom G 

Tucson, AZ

(Private)

Avery Therapeutics is a late-stage pre-clinical company developing a new class of restorative medicine for patients with intractable diseases of inflammation and fibrosis by levering the therapeutic potential within the immune system. Avery’s lead clinical candidate AT-102 uses our proprietary MPhase biologic platform to address heart failure, one of the leading causes of death in the world. In pre-clinical models, AT-102 structures the heart to improve and establishes best-in-class efficacy.

www.averythera.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions